biotech · Non-muscle Invasive Bladder Cancer · Intestinal Failure · TARA
Protara Therapeutics
Protara Therapeutics is a biotech organization headquartered in New York, USA. It trades on NYSE under ticker TARA. Primary therapeutic focus areas include Non-muscle Invasive Bladder Cancer, Intestinal Failure, Choline
New York, USA HQ
2017 Founded
56 Employees
Public company Type
TARA · NYSE Ticker
Company details
- Status
- Public
- HQ
- New York, USA
- Founded
- 2017
- Employees
- 56
- Programs
- 7
- Drugs
- 10
- Patents
- 2
TARA-002
Phase 3 · small molecule · Bladder (Urothelial, Transitional Cell) Cancer
TARA-002 for Bladder (Urothelial, Transitional Cell) Cancer is a Phase 3 program (small_molecule) at Protara Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code TARA-002-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Protara Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Bladder (Urothelial, Transitional Cell) Cancer
- Status
- active
- Trials
- 1